Elevar Therapeutics Announces Appointment of New Member to the Board of Directors
SALT LAKE CITY, USA, September 16, 2019
Elevar Therapeutics is pleased to announce the addition of a new member to the Board of Directors, Paul Chen.
“We are very excited to have Paul join our Board of Directors,” said Alex Kim, Elevar Therapeutics’ CEO, “Paul is a serial entrepreneur with multiple successful hits with new molecules, most notably as the inventor of rivoceranib.”
Mr. Chen has over 36 years of experience in the pharmaceutical industry with hands-on experience from discovery to preclinical to clinical development. As an inventor, he has authored almost 30 patents covering novel compounds and derivatives, including rivoceranib (commonly known as apatinib). Mr. Chen has worked at a variety of companies from small startups to established pharmaceutical companies such as Amgen. He also founded his own company, Advenchen Laboratories in Southern California which is the licensor of rivoceranib to Jiangsu Hengrui (China) and Elevar Therapeutics (rest of world).
About Elevar Therapeutics
Elevar Therapeutics (formerly LSK BioPharma) is a privately held biopharmaceutical company with offices in Utah, California, and South Korea. The Company aims to provide patients and their caregivers with exceptional choices for effective and well-tolerated therapies. Elevar Therapeutics’ lead proprietary drug candidate is rivoceranib, a selective VEGFR-2 inhibitor which has demonstrated clinical efficacy in a variety of solid tumors. Elevar Therapeutics can be found on the web at www.elevartherapeutics.com.